Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2. This evidence concerns the gene EIF5A2 and non-small cell lung carcinoma.